Amgen Price Target Raised to $425.00/Share From $350.00 by JP Morgan

What happened

JP Morgan raised its price target for Amgen to $425.00 per share from $350.00 per share. The supplied article also says JP Morgan maintained its Neutral rating on Amgen.

Confirmed

Global impact / market context

A higher price target signals that JP Morgan sees more potential value in Amgen shares than its previous target indicated, but the unchanged Neutral rating shows it did not shift to a more positive or negative overall view. Investors may compare the target with their own expectations.

Analyst inference

The supplied report contains only the target change and the maintained Neutral rating, with no explanation of JP Morgan’s reasoning, earnings outlook, or expected business changes. It therefore offers limited information about possible effects on Amgen’s revenue, costs, or cash available.

Analyst inference

What to watch

1. Look for any later explanation from JP Morgan describing what prompted the higher target and whether its view of Amgen’s expected business performance has changed. Analyst inference
2. Watch for any change in JP Morgan’s rating; the report says Neutral remained in place alongside the higher price target. Confirmed
3. Compare future company updates on revenue, costs, and cash available with the assumptions behind the target, if those assumptions are later disclosed. Analyst inference

Evidence

• Original source link unavailable